Author:
Marie Aya A.,Hammad Sherin F.,Salim Mohamed M.,Elkhodary Mahmoud M.,Kamal Amira H.
Abstract
AbstractA reversed-phase RP-HPLC method was developed for the simultaneous determination of metformin hydrochloride (MET), pioglitazone (PIO), and glimepiride (GLM) in their combined dosage forms and spiked human plasma. Quality risk management principles for determining the critical method parameters (CMPs) and fractional factorial design were made to screen CMPs and subsequently, the Box–Behnken design was employed. The analytical Quality by Design (AQbD) paradigm was used to establish the method operable design region (MODR) for the developed method depended on understanding the quality target product profile (QTPP), analytical target profile (ATP), and risk assessment for different factors that affect the method performance to develop an accurate, precise, cost-effective, and environmentally benign method. The separation was carried out using a mobile phase composed of methanol: 0.05 M potassium dihydrogen phosphate buffer pH 3.7 with 0.05% TEA (78:22, v/v). The flow rate was 1.2 mL/min. DAD detector was set at 227 nm. Linagliptin (LIN) was used as an internal standard. The proposed method was validated according to The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). The assay results obtained by using the developed method were statistically compared to those obtained by the reported HPLC method, and a satisfying agreement was observed.
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Hegazi, R., El-Gamal, M., Abdel-Hady, N. & Hamdy, O. Epidemiology of and risk factors for type 2 diabetes in Egypt. Ann. Glob. Health 81, 814–820 (2015).
2. Bailey, C. J. & Turner, R. C. Metformin. N. Engl. J. Med. 334, 574–579 (1996).
3. Varaprasad, C., Asif, M. & Ramakrishna, K. RP-HPLC method for simultaneous estimation of Metformin and linagliptin in the tablet dosage form. Rasayan J. Chem. 8, 426–432 (2015).
4. Gillies, P. S. & Dunn, C. Pioglitazone. Drugs 60, 333–343 (2000).
5. Charpentier, G., Halimi, S., Investigators, F. P. S. & Metabolism. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes. J. 11, 844–854 (2009).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献